Follow
Arpita Pal
Arpita Pal
Senior Scientist
Verified email at alumni.purdue.edu - Homepage
Title
Cited by
Cited by
Year
MicroRNA-223 suppresses the canonical NF-κB pathway in basal keratinocytes to dampen neutrophilic inflammation
W Zhou, AS Pal, AYH Hsu, T Gurol, X Zhu, SE Wirbisky-Hershberger, ...
Cell reports 22 (7), 1810-1823, 2018
1182018
Animal models to study microRNA function
AS Pal, AL Kasinski
Advances in cancer research 135, 53-118, 2017
702017
Cigarette smoke condensate promotes pro‐tumourigenic stromal–epithelial interactions by suppressing miR‐145
A Pal, G Melling, EE Hinsley, TD Kabir, HE Colley, C Murdoch, ...
Journal of oral pathology & medicine 42 (4), 309-314, 2013
362013
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
AS Pal, M Bains, A Agredo, AL Kasinski
Biochemical pharmacology 189, 114154, 2021
282021
Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of MET
AS Pal, A Agredo, NA Lanman, J Son, IS Sohal, M Bains, C Li, ...
Cancer research 82 (8), 1534-1547, 2022
252022
Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510
AS Pal, AM Agredo, NA Lanman, J Clingerman, K Gates, AL Kasinski
BioRxiv, 2020.03. 17.995951, 2020
32020
Loss of the methyltransferase KMT5C drives resistance to tyrosine kinase inhibitors via H4K20me3 regulation in non-small cell lung cancer
A Agredo, A Pal, J Son, NA Lanman, AL Kasinski
Cancer Research 83 (7_Supplement), 4752-4752, 2023
12023
In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones
AS Pal, AM Agredo, AL Kasinski
Bio-protocol 12 (16), e4489-e4489, 2022
12022
Aberrantly expressed microRNAs drive the development of acquired Erlotinib resistance in non-small cell lung cancer
AS Pal, A Agredo, AL Kasinski
Cancer Research 77 (13_Supplement), 3142-3142, 2017
12017
A GPRC5D and BCMA bispecific CAR-T product demonstrated dual antigen targeting capability and efficacy against multiple myeloma cells bearing BCMA mutations associated with …
W Chang, C.-W., Luo, Y., Pal, A.S., Ding, H., Lai, Y.-S., Guan, S., Lan, W., Li
Journal for ImmunoTherapy of Cancer 12, A284, 2024
2024
Loss of SUV420H2 drives EGFR inhibitor resistance in EGFR mutant NSCLC cell lines
A Agredo, A Pal, N Lanman, J Son, AL Kasinski
Cancer Research 82 (12_Supplement), 1104-1104, 2022
2022
Identification of novel epigenetic mediators of erlotinib resistance in non-small cell lung cancer
AS Pal
Purdue University, 2020
2020
Suppression of NF‐κB Activation in Basal Keratinocytes Via Cell Autonomous and Non‐Autonomous Functions of MicroRNA‐223
W Zhou, AYH Hsu, T Gurol, X Zhu, SE Wirbisky, AS Pal, AL Kasinski, ...
Available at SSRN 3155596, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–13